# Puma Biotechnology

Source: https://onco.cc/companies/puma-biotechnology/  
OnCo record `puma-biotechnology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Puma Biotechnology developed neratinib (Nerlynx), the extended-adjuvant HER2 pill.

## Summary

Puma Biotechnology, based in Los Angeles and listed as PBYI, is a single-product company that developed neratinib, sold as Nerlynx, the extended-adjuvant HER2 tablet for breast cancer. Neratinib was approved in 2017 for extended adjuvant use and in 2020 for metastatic HER2-positive disease in combination with capecitabine, and the company is also developing alisertib, an Aurora A kinase inhibitor. OnCo links it to HER2-positive breast cancer and to the neratinib drug record. Whether extended adjuvant HER2 blockade still adds value as earlier treatment improves is the open question for its one marketed product. Neratinib has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-07
- HQ: Los Angeles, CA
- Type: biotech
- Website: https://www.pumabiotechnology.com
- Ticker: PBYI

## Sources

- Official website: https://www.pumabiotechnology.com

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Alisertib](https://onco.cc/drugs/alisertib/), [Neratinib](https://onco.cc/drugs/neratinib/)
- trials: [A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)](https://onco.cc/trials/nct07465757/), [A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer](https://onco.cc/trials/nct06369285/), [A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer](https://onco.cc/trials/nct06095505/), [NALA](https://onco.cc/trials/nala/)

---
JSON: https://onco.cc/api/v1/entities/puma-biotechnology.json